Abstract
BackgroundReceptor for advanced glycation end products (RAGE) is a multi-ligand transmembrane receptor of the immunoglobulin superfamily. Lysophosphatidic acid (LPA) is a ligand for RAGE and is involved in physiological and pathophysiological conditions including cancer. However, RAGE-LPA axis is unexplored in lung and mammary cancer.MethodsRAGE was silenced in A549, MDA MB-231 and MCF7 using RAGE shRNA. For in vitro tumorigenesis, we performed wound healing, colony formation, cell proliferation and invasion assays. Evaluation of expression of oncogenes, EMT markers and downstream signaling molecules was done by using western blot and immunohistochemistry. For subcellular expression of RAGE, immunofluorescence was done. In vivo tumorigenesis was assessed by intraperitoneal injection of cancer cells in nude mice.ResultsHere we show RAGE mediated profound increase in proliferation, migration and invasion of lung and mammary cancer cells via LPA in Protein kinase B (PKB) dependent manner. LPA mediated EMT transition is regulated by RAGE. In vivo xenograft results show significance of RAGE in LPA mediated lung and mammary tumor progression, angiogenesis and immune cell infiltration to tumor microenvironment.ConclusionOur results establish the significance and involvement of RAGE in LPA mediated lung and mammary tumor progression and EMT transition via RAGE. RAGE-LPA axis may be a therapeutic target in lung and mammary cancer treatment strategies.EdVB1f1yrz4Do4i3nWt_5KVideo
Highlights
Receptor for advanced glycation end products (RAGE) is a multi-ligand transmembrane receptor of the immunoglobulin superfamily
Our results confirmed the activation of ERK and Protein kinase B (PKB) pathways in nonsmall cell lung carcinoma (NSCLC) A549 cells via RAGE
We checked the epithelial to mesenchymal transition marker and found twist1 to be upregulated by Lysophosphatidic acid (LPA) treatment in A549 cells and RAGE silencing led to decrease in the level of twist1 after LPA treatment suggesting its role in metastasis of A549 cells (Fig. 1c)
Summary
Receptor for advanced glycation end products (RAGE) is a multi-ligand transmembrane receptor of the immunoglobulin superfamily. Lysophosphatidic acid (LPA) is a ligand for RAGE and is involved in physiological and pathophysiological conditions including cancer. RAGE-LPA axis is unexplored in lung and mammary cancer. Receptor for advanced glycation end products (RAGE) is a multi-ligand transmembrane receptor belonging to immunoglobulin superfamily. RAGE extracellular domain binds to various ligands including advanced glycation end products (AGEs), amyloid beta (aβ), S100B proteins/calgranulins, high mobility group box proteins (HMGB1), phosphatidylserine and lysophosphatidic acid (LPA) [13,14,15,16]. RAGE is found to be associated with tumor progression in glioma, bladder, melanoma, liver, pancreatic, prostate, colorectal, ovarian, gastric and lung cancer [15, 17,18,19]. Blocking RAGE signaling inhibits cancer cell growth in vitro and reduce tumorigenicity in murine models [21, 22]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.